Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast 2018; 44:81-89.
Dec 20, 2018Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Dec 20, 2018Breast 2018; 44:81-89
Deniz Miriam, Andergassen Ullrich, Steidl Julia, Trapp Elisabeth, Fasching Peter A, Häberle Lothar, Beckmann Matthias W, Schneeweiss Andreas, Schrader Iris, Janni Wolfgang, Rack Brigitte, Jueckstock Julia, Kost Bernd, deGregorio Amelie, DeGregorio Nikolaus, Bekes Inga, Widschwendter Peter, Schochter Fabienne, Ernst Kristina, Scholz Christoph, Bauer Emanuel Ca, Aivazova-Fuchs Viktoria, Weissenbacher Tobias, Friedl Thomas Wp
Seminal vesicle sparing robotic radical prostatectomy - no different interpretation of postoperative PSA follow-up required?
Betschart P, Omlin A, Abt D. Seminal vesicle sparing robotic radical prostatectomy - no different interpretation of postoperative PSA follow-up required?. Swiss Med Wkly 2018; 148:w14698.
Dec 15, 2018Seminal vesicle sparing robotic radical prostatectomy - no different interpretation of postoperative PSA follow-up required?
Dec 15, 2018Swiss Med Wkly 2018; 148:w14698
Betschart Patrick, Omlin Aurelius, Abt Dominik
Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Kienle D, Andrieu C, Bernhard J, Lugli A, Baertschi D, Helbling D, Saletti P, Kueng M, Bastian S, Horber D, Koeberle D, Winterhalder R, Quagliata L, Wicki A, Ribi K, Dietrich D, von Moos R. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol 2018; 10:304-310.
Dec 14, 2018Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
Dec 14, 2018J Geriatr Oncol 2018; 10:304-310
Kienle Dirk L, Andrieu Christiane, Bernhard Juerg, Lugli Alessandro, Baertschi Daniela, Helbling Daniel, Saletti Piercarlo, Kueng Marc, Bastian Sara, Horber Daniel, Koeberle Dieter, Winterhalder Ralph C, Quagliata Luca, Wicki Andreas, Ribi Karin, Dietrich Daniel, von Moos Roger
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Management of HER2-Positive Early Breast Cancer
Steger G, Luftner D, Stöger H, Thürlimann B, Untch M. Management of HER2-Positive Early Breast Cancer. Breast Care (Basel) 2018; 13:453-455.
Dec 5, 2018Management of HER2-Positive Early Breast Cancer
Dec 5, 2018Breast Care (Basel) 2018; 13:453-455
Steger Günther, Luftner Diana, Stöger Herbert, Thürlimann Beat, Untch Michael
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Schneeweiss A, Ingold-Heppner B, Blohmer J, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, von Minckwitz G, Thomalla J, Jackisch C, Kast K, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Loibl S. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer 2018; 106:181-192.
Dec 5, 2018Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial
Dec 5, 2018Eur J Cancer 2018; 106:181-192
Schneeweiss Andreas, Ingold-Heppner Barbara, Blohmer Jens-Uwe, Rezai Mahdi, Frank Matthias, Engels Knut, Rhiem Kerstin, Fasching Peter Andreas, Nekljudova Valentina, von Minckwitz Gunter, Thomalla Jörg, Jackisch Christian, Kast Karin, Möbus Volker, Tesch Hans, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Huober Jens, Klare Peter, Kümmel Sherko, Untch Michael, Loibl Sibylle
Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
Henke G, Kurzeder C, Gyr A, Ballardini B, Matrai Z, Gnant M, Fitzal F, Hawle H, Ackerknecht M, Muenst S, Zwahlen D, Ruhstaller T, Gerard M, Hayoz S, Ribi K, Knauer M, Weber W. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials 2018; 19:667.
Dec 4, 2018Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial
Dec 4, 2018Trials 2018; 19:667
Henke Guido, Kurzeder Christian, Gyr Andreas, Ballardini Bettina, Matrai Zoltan, Gnant Michael, Fitzal Florian, Hawle Hanne, Ackerknecht Markus, Muenst Simone, Zwahlen Daniel R, Ruhstaller Thomas, Gerard Marie-Aline, Hayoz Stefanie, Ribi Karin, Knauer Michael, Weber Walter P
Consensus on molecular imaging and theranostics in prostate cancer
Fanti S, Montironi R, Ost P, O'Sullivan J, Padhani A, Schalken J, Scher H, Tombal B, van Moorselaar R, Van Poppel H, Vargas H, Walz J, Weber W, Wester H, Lecouvet F, Hicks R, Herrmann K, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, de Bono J, Fizazi K, Gillessen Sommer S, Gledhill S, Haberkorn U, Oyen W. Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncol 2018; 19:e696-e708.
Dec 1, 2018Consensus on molecular imaging and theranostics in prostate cancer
Dec 1, 2018Lancet Oncol 2018; 19:e696-e708
Fanti Stefano, Montironi Rodolfo, Ost Piet, O'Sullivan Joe M, Padhani Anwar R, Schalken Jack A, Scher Howard I, Tombal Bertrand, van Moorselaar R Jeroen A, Van Poppel Heindrik, Vargas Hebert Alberto, Walz Jochen, Weber Wolfgang A, Wester Hans-Jürgen, Lecouvet Frederic, Hicks Rodney J, Herrmann Ken, Minozzi Silvia, Antoch Gerald, Banks Ian, Briganti Alberto, Carrio Ignasi, Chiti Arturo, Clarke Noel, Eiber Matthias, de Bono Johann, Fizazi Karim, Gillessen Sommer Silke, Gledhill Sam, Haberkorn Uwe, Oyen Wim J G
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
Rageth C, Morris E, Boos A, Sonnenschein M, Malhaire C, Knauer M, Dellas S, Foschini M, Fallenberg E, Baltzer P, Dammann F, Tausch C, Decker T, Mundinger A, Kubik-Huch R, Pinker K, O'Flynn E, Varga Z. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2018
Nov 30, 2018Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
Nov 30, 2018Breast Cancer Res Treat 2018
Rageth Christoph J, Morris Elisabeth, Boos Andreas, Sonnenschein Martin, Malhaire Caroline, Knauer Michael, Dellas Sophie, Foschini Maria P, Fallenberg Eva Maria, Baltzer Pascal A, Dammann Florian, Tausch Christoph, Decker Thomas, Mundinger Alexander, Kubik-Huch Rahel A, Pinker Katja, O'Flynn Elizabeth A M, Varga Zsuzsanna
Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Müller J, von Schulthess G, Kaufmann P, Kranzbuehler H, John H, Zilli T, Müller A, Omlin A, Schmid D, Sulser T, Kroeze S, Guckenberger M, Eberli D, Kedzia S, Garcia Schüler H, Muehlematter U, Ferraro D, Burger I. Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction. Eur J Nucl Med Mol Imaging 2018
Nov 28, 2018Clinical impact of Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction
Nov 28, 2018Eur J Nucl Med Mol Imaging 2018
Müller Julian, von Schulthess Gustav K, Kaufmann Philipp A, Kranzbuehler Helmut, John Hubert, Zilli Thomas, Müller Alexander, Omlin Aurelius, Schmid Daniel M, Sulser Tullio, Kroeze Stephanie G C, Guckenberger Matthias, Eberli Daniel, Kedzia Sarah, Garcia Schüler Helena I, Muehlematter Urs J, Ferraro Daniela A, Burger Irene A
Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer
Siano M, Espeli V, Jörger M. Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer. Tumori 2018:300891618811276.
Nov 26, 2018Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer
Nov 26, 2018Tumori 2018:300891618811276
Siano Marco, Espeli Vittoria, Jörger Markus
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Ruhstaller T, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber R, Coates A, Goldhirsch A, Thürlimann B, Regan M, Veyret C, Del Mastro L, Giobbie-Hurder A, Colleoni M, Jensen M, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen E, Gladieff L, Bonnefoi H, Harvey V, Spazzapan S, Tondini C, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol 2018:JCO1800440.
Nov 26, 2018Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
Nov 26, 2018J Clin Oncol 2018:JCO1800440
Ruhstaller Thomas, Simoncini Edda, Gianni Lorenzo, Rochlitz Christoph, Kralidis Elena, Zaman Khalil, Jassem Jacek, Piccart-Gebhart Martine, Di Leo Angelo, Gelber Richard D, Coates Alan S, Goldhirsch Aron, Thürlimann Beat, Regan Meredith M, Veyret Corinne, Del Mastro Lucia, Giobbie-Hurder Anita, Colleoni Marco, Jensen Maj-Britt, Ejlertsen Bent, de Azambuja Evandro, Neven Patrick, Láng István, Jakobsen Erik Hugger, Gladieff Laurence, Bonnefoi Hervé, Harvey Vernon J, Spazzapan Simon, Tondini Carlo, members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group
Review on current treatment options for lesions of uncertain malignant potential (B3 lesions) of the breast: do B3 papillary lesions need to be removed in any case by open surgery?
Bekes I, deGregorio A, De Waal A, Nerlich A, deWaal J, Janni W, Ebner F. Review on current treatment options for lesions of uncertain malignant potential (B3 lesions) of the breast: do B3 papillary lesions need to be removed in any case by open surgery?. Arch Gynecol Obstet 2018; 300:481-484.
Nov 26, 2018Review on current treatment options for lesions of uncertain malignant potential (B3 lesions) of the breast: do B3 papillary lesions need to be removed in any case by open surgery?
Nov 26, 2018Arch Gynecol Obstet 2018; 300:481-484
Bekes Inga, deGregorio Amelie, De Waal Adrian, Nerlich Andreas, deWaal Johann, Janni Wolfgang, Ebner Florian K
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Sinn H, Hirsmüller S, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Nöthlings U, Müller V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Stangl S, Paradies K, Wöckel A, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P, Jírů-Hillmann S, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Siedentopf F, Lebeau A, König K, Hahne A, Baumgartner T, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Honegger C. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:1056-1088.
Nov 26, 2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Nov 26, 2018Geburtshilfe Frauenheilkd 2018; 78:1056-1088
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Fasching Peter, Sinn Hans-Peter, Hirsmüller Susanne, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Tesch Hans, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Buck Andreas, Nöthlings Ute, Müller Volkmar, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Möbus Volker, Stangl Stephanie, Paradies Kerstin, Wöckel Achim, Kühn Thorsten, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Krockenberger Mathias, Heuschmann Peter U, Jírů-Hillmann Steffi, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, Petersen Cordula, Bartsch Hans Helge, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Siedentopf Friederike, Lebeau Annette, König Klaus, Hahne Andrea, Baumgartner Traudl, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Honegger Christoph
Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital
De Gregorio A, Widschwendter P, Albrecht S, De Gregorio N, Friedl T, Huober J, Janni W, Ebner F. Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital. Geburtshilfe Frauenheilkd 2018; 78:1138-1145.
Nov 26, 2018Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years - Comparison of a University Center and a Community Hospital
Nov 26, 2018Geburtshilfe Frauenheilkd 2018; 78:1138-1145
De Gregorio Amelie, Widschwendter Peter, Albrecht Susanne, De Gregorio Nikolaus, Friedl Thomas W P, Huober Jens, Janni Wolfgang, Ebner Florian K
Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer
Lam T, De Santis M, Fanti S, Briers E, van den Bergh R, Schoots I, Moris L, Gross T, Fossati N, Gillessen Sommer S, Grummet J, Van Poppel H, N'Dow J, Wiegel T, Tilki D, Rouvière O, van der Kwast T, van der Poel H, Henry A, Cumberbatch M, Van den Broeck T, Dell'Oglio P, Davis N, Donaldson J, Cornford P, Mason M, Willemse P, Plass K, MacLennan S, Fankhauser C, Grivas N, Buddingh K, Zattoni F, Omar M, Paterson C, Pang K, Liew M, Lardas M, Ingels A, Mottet N. Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. Eur Urol 2018
Nov 22, 2018Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer
Nov 22, 2018Eur Urol 2018
Lam Thomas B L, De Santis Maria, Fanti Stefano, Briers Erik, van den Bergh Roderick C N, Schoots Ivo G, Moris Lisa, Gross Tobias, Fossati Nicola, Gillessen Sommer Silke, Grummet Jeremy P, Van Poppel Hendrik, N'Dow James, Wiegel Thomas, Tilki Derya, Rouvière Olivier, van der Kwast Theodorus H, van der Poel Henk G, Henry Ann M, Cumberbatch Marcus G, Van den Broeck Thomas, Dell'Oglio Paolo, Davis Niall F, Donaldson James, Cornford Philip, Mason Malcolm D, Willemse Peter-Paul M, Plass Karin, MacLennan Steven, Fankhauser Christian, Grivas Nikos, Buddingh Karel T, Zattoni Fabio, Omar Muhammad I, Paterson Catherine, Pang Karl H, Liew Matthew, Lardas Michael, Ingels Alexandre, Mottet Nicolas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
Nov 8, 2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Nov 8, 2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
Griesinger F, Gautschi O, Früh M, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J. [Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. Pneumologie 2018; 72:774-781.
Nov 8, 2018[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]
Nov 8, 2018Pneumologie 2018; 72:774-781
Griesinger F, Gautschi O, Früh Martin, Pirker R, Wiewrodt R, Brugger W, Schulz C, Sebastian M, Kimmich M, Deschler-Baier B, Lüers A, Radke S, Wolf J
Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Powles R, Pusztai L, Elemento O, Piccart-Gebhart M, Baselga J, Huober J, Di Cosimo S, Sarp S, de Azambuja E, Harbeck N, Nuciforo P, Fumagalli D, Loi S, Sotiriou C, Redmond D, Hatzis C. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 2018; 4:e181564.
Nov 8, 2018Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Nov 8, 2018JAMA Oncol 2018; 4:e181564
Powles Ryan L, Pusztai Lajos, Elemento Olivier, Piccart-Gebhart Martine, Baselga José, Huober Jens, Di Cosimo Serena, Sarp Severine, de Azambuja Evandro, Harbeck Nadia, Nuciforo Paolo, Fumagalli Debora, Loi Sherene, Sotiriou Christos, Redmond David, Hatzis Christos
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone Marrow Transplant 2018
Nov 2, 2018Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Nov 2, 2018Bone Marrow Transplant 2018
Ghilardi Guido, Ghielmini Michele, Wannesson Luciano, Lerch Erika, Samaras Panagiotis, Schanz Urs, Passweg Jakob R, Stussi Georg, Kleber Martina, Gerber Bernhard, Rossi Davide, Schmidt Adrian, Pabst Thomas, Jeker Barbara, Müller Rouven, Cairoli Anne, Müller Antonia M S, Bargetzi Mario, Hitz Felicitas, Baldomero Helen, Heim Dominik, Swiss Blood Stem Cell Transplantation Registry